ECSP22091230A - Derivados de n-(piperidin-4-il)benzamida de acción luminal - Google Patents

Derivados de n-(piperidin-4-il)benzamida de acción luminal

Info

Publication number
ECSP22091230A
ECSP22091230A ECSENADI202291230A ECDI202291230A ECSP22091230A EC SP22091230 A ECSP22091230 A EC SP22091230A EC SENADI202291230 A ECSENADI202291230 A EC SENADI202291230A EC DI202291230 A ECDI202291230 A EC DI202291230A EC SP22091230 A ECSP22091230 A EC SP22091230A
Authority
EC
Ecuador
Prior art keywords
luminal
piperidin
action
benzamide derivatives
compounds
Prior art date
Application number
ECSENADI202291230A
Other languages
English (en)
Inventor
Tony S Gibson
Steve Swann
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP22091230A publication Critical patent/ECSP22091230A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de Fórmula 1 y sales farmacéuticamente aceptables de estos, en donde m, R1, R2, R3, R4, R5, R6, X1, X2, X3 y X4 se definen la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de Fórmula 1, a composiciones farmacéuticas que los contienen y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con el receptor 5-HT4.
ECSENADI202291230A 2020-05-04 2022-11-28 Derivados de n-(piperidin-4-il)benzamida de acción luminal ECSP22091230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019829P 2020-05-04 2020-05-04
PCT/US2021/030493 WO2021225968A1 (en) 2020-05-04 2021-05-03 Luminally-acting n-(piperidin-4-yl)benzamide derivatives

Publications (1)

Publication Number Publication Date
ECSP22091230A true ECSP22091230A (es) 2023-02-28

Family

ID=76060006

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202291230A ECSP22091230A (es) 2020-05-04 2022-11-28 Derivados de n-(piperidin-4-il)benzamida de acción luminal

Country Status (17)

Country Link
US (1) US20230158010A1 (es)
EP (1) EP4146625A1 (es)
JP (1) JP2023525986A (es)
KR (1) KR20230005893A (es)
CN (1) CN115515933A (es)
AR (1) AR122005A1 (es)
AU (1) AU2021266690A1 (es)
BR (1) BR112022022184A2 (es)
CA (1) CA3182379A1 (es)
CL (1) CL2022003067A1 (es)
CO (1) CO2022015823A2 (es)
EC (1) ECSP22091230A (es)
IL (1) IL297456A (es)
MX (1) MX2022013745A (es)
PE (1) PE20231375A1 (es)
TW (1) TW202208333A (es)
WO (1) WO2021225968A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법

Also Published As

Publication number Publication date
AR122005A1 (es) 2022-08-03
CN115515933A (zh) 2022-12-23
AU2021266690A1 (en) 2022-11-10
CL2022003067A1 (es) 2023-07-14
KR20230005893A (ko) 2023-01-10
PE20231375A1 (es) 2023-09-07
MX2022013745A (es) 2022-11-16
BR112022022184A2 (pt) 2023-01-17
EP4146625A1 (en) 2023-03-15
CO2022015823A2 (es) 2022-11-18
IL297456A (en) 2022-12-01
TW202208333A (zh) 2022-03-01
US20230158010A1 (en) 2023-05-25
JP2023525986A (ja) 2023-06-20
WO2021225968A1 (en) 2021-11-11
CA3182379A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
UY38602A (es) Compuestos tricíclicos condensados
NI202000078A (es) Compuestos heteroaril tetracíclicos
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
ECSP20062464A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
CO2021014155A2 (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
DOP2023000267A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
ECSP22049160A (es) Derivados de bencimidazol
CO2024002844A2 (es) Compuestos espirocíclicos
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2023000117A2 (es) Derivados de sulfona
AR019322A1 (es) Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
ECSP22082219A (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina
AR049638A1 (es) Derivados de benzileter, su elaboracion, su uso para preparar agentes farmaceuticos y composicion farmaceutica
AR124720A1 (es) Derivados de pirazolamida